Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy

What this episode covers

For the complete activity, including supporting material, please visit https://www.peervoice.com/TZX860. Presented by Jonathan Barratt, PhD, FRC. Learning Objectives: Describe the relationship between the multi-hit hypothesis and disease trajectory in patients with IgA nephropathy (IgAN); Summarise the role and therapeutic implications of complement pathway dysregulation in IgAN disease progression; Differentiate between emerging therapeutic targets under investigation in patients with IgAN; Interpret data from clinical trials examining emerging therapies, including complement inhibitors, in the context of emerging guidance and approaches to IgAN management.